07:00 , May 23, 2016 |  BioCentury  |  Finance

Herding an atypical syndicate

Unlike its gene editing peers that are going deep into therapeutics, Caribou Biosciences Inc. has been going wide, exploring numerous sectors where its CRISPR- Cas9 technology could be applied. With last week's $30 million series...
07:00 , May 23, 2016 |  BC Week In Review  |  Financial News

Caribou Biosciences completes venture financing

Caribou Biosciences Inc. , Berkeley, Calif.   Business: Genomics, Infectious   Date completed: 2016-05-16   Type: Venture financing   Raised: $30 million   Investors: Anterra Capital; Heritage Group; Maverick Capital; Pontifax AgTech; F-Prime Capital Partners;...
01:11 , May 17, 2016 |  BC Extra  |  Financial News

Caribou raises $30M series B

CRISPR company Caribou Biosciences Inc. (Berkeley, Calif.) raised $30 million in a series B round. New investors Anterra Capital, Heritage Group, Maverick Capital and Pontifax AgTech joined existing investors F-Prime Capital, Novartis AG (NYSE:NVS; SIX:NOVN),...
07:00 , Apr 6, 2015 |  BC Week In Review  |  Financial News

Caribou Biosciences completes venture financing

Caribou Biosciences Inc. , Berkeley, Calif.   Business: Genomics, Infectious   Date completed: 2015-04-02   Type: Venture financing   Raised: $11 million   Investors: Fidelity; Novartis AG ; Mission Bay Capital LLC; 5 Prime Ventures;...
01:21 , Apr 3, 2015 |  BC Extra  |  Financial News

Caribou raises $11M in series A

Gene editing company Caribou Biosciences Inc. (Berkeley, Calif.) raised $11 million in an untranched series A round from Fidelity Bioscience; Novartis; Mission Bay Capital; 5 Prime Ventures; and an undisclosed strategic partner. Jennifer Doudna, a...